AbbVie $ABBV just reported earnings!

EPS: $2.31 (est $2.23) ✅

Revenue: $12.31B (est $11.94B) ✅

Raises EPS guidance ✅

Shares are up 1% pre market!

#ICYMI : This morning we released our Q1 2024 #FinancialResults . Read more about our performance: news.abbvie.com/2024-04-26-Abb… $ABBV #earnings

AbbVie ends pharma earnings week on a high note!
Their immunology drugs powered strong Q1 results, exceeding expectations. They even raised their 2024 outlook! But Humira sales continue to slide (-35%). #pharma #earnings #biotech

Och AbbVie rapporterar bättre än förväntat.
...

$ABBV | AbbVie Q1 FY24 Earnings Highlights:

🔹 Adjusted EPS: $2.31 (Est. $2.23) 🟢
🔹 Revenue: $12.31B (Est. $11.94B) 🟢
🔹 Raised FY'24 EPS Guidance

Revenue by Portfolio:
🔸 Immunology Portfolio: $5.371B; DOWN -3.9%
🔸 Neuroscience Portfolio: $1.965B; UP +15.9% YoY
🔸…

$ABBV | AbbVie Q1 24Earnings:
- Adj EPS: $2.31 (est $2.23)
- Revenue: $12.31B (est $11.94B)
- Sees FY Adj EPS $11.13 To $11.33, Saw $10.97 - $11.17
- Humira Rev $2.27B (est $2.24B)

AbbVie lifts profit forecast after Skyrizi sales beat expectations reut.rs/3JBvIzT

AbbVie Is ‘Firing On All Cylinders,’ But Its Stock Isn’t.

hataf.co/yahoo-finance-…

AbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That investors.com/news/technolog…

AbbVie $ABBV
Q1決算発表
⭕️EPS予想$2.26 結果$2.31
⭕️売上高予想$11.94B 結果$12.31B (+0.7% Y/Y)
ガイダンスFY24
⭕️EPS予想$11.12 新$11.13~$11.33

AbbVie tries to reassure investors on Humira biosimilar threat biopharmadive.com/news/abbvie-hu… Jon Gardner $ABBV - 5%

Jim Cramer's quick thoughts on 5 stocks: Chevron, Snap, Intel, AbbVie and Colgate cnbc.com/2024/04/26/jim…

[ #米国株 決算速報]
アッヴィ (Abbvie) $ABBV 決算
⭕️売上高 結果:$123.1億 ∕ 予想: $119.3億
⭕️EPS 結果: $2.31 ∕ 予想: $2.27

売上高・EPSともに予想を上回りました💨
#企業分析 #株クラの輪を拡げよう

#lizjny AbbVie was founded in 2013 when we became a separate company from Abbott.

Nachdem es gestern nachbörslich richtig rund ging 📈, gibt es keine Verschnaufpause an der Börse 🥵 Heute gibt es Ergebnisse von
-ExxonMobil 🛢
-Chevron 🛢
-Abbvie 💊
-Safran ✈
-Colgate-Palmolive 🪥
-AON 📑
-Roper Technologies 🤖
-Lyondellbasell 🧪
-Evolution AB 🎰
#finx

Top-line results: Attention! Abbvie Inc ($ABBV 🚀Stock Price: $160.09) reveals a major update on RINVOQ (upadacitinib) for Moderate to Severe Atopic Dermatitis. Game changer?

Click for More: ainvest.onelink.me/MpR9/33tz0xdi

#Investing #stockintelligence #StockTrading

abbvie copay assistance program out here saving lives. the insurance companies are the enemy y’all

$ABBV 1Q returns to top line growth
1Q YoY
Revenue +0.7% ($12.3 B, above guidance)
Humira -36%
Skyrizi +48%
Rinvoq +59%
Net income +473%
Dil. EPS +492% (adj -6%)

Raises Adj. dil. EPS guidance for FY24 from $10.97 - $11.17 to $11.13 - $11.33

news.abbvie.com/2024-04-26-Abb…

Earnings von AbbVie (ABBV).